• Jorge L Ruas, James P White, Rajesh R Rao, Sandra Kleiner, Kevin T Brannan, Brooke C Harrison, Nicholas P Greene, Jun Wu, Jennifer L Estall, Brian A Irving, Ian R Lanza, Kyle A Rasbach, Mitsuharu Okutsu, K Sreekumaran Nair, Zhen Yan, Leslie A Leinwand, and Bruce M Spiegelman.
• Department of Cell Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. jorge.ruas@ki.se
• Cell. 2012 Dec 7;151(6):1319-31.

AbstractPGC-1α is a transcriptional coactivator induced by exercise that gives muscle many of the best known adaptations to endurance-type exercise but has no effects on muscle strength or hypertrophy. We have identified a form of PGC-1α (PGC-1α4) that results from alternative promoter usage and splicing of the primary transcript. PGC-1α4 is highly expressed in exercised muscle but does not regulate most known PGC-1α targets such as the mitochondrial OXPHOS genes. Rather, it specifically induces IGF1 and represses myostatin, and expression of PGC-1α4 in vitro and in vivo induces robust skeletal muscle hypertrophy. Importantly, mice with skeletal muscle-specific transgenic expression of PGC-1α4 show increased muscle mass and strength and dramatic resistance to the muscle wasting of cancer cachexia. Expression of PGC-1α4 is preferentially induced in mouse and human muscle during resistance exercise. These studies identify a PGC-1α protein that regulates and coordinates factors involved in skeletal muscle hypertrophy.Copyright © 2012 Elsevier Inc. All rights reserved.

30 keywords...

hide…